William Blair analyst Andrew Brackmann has maintained their bullish stance on SERA stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Brackmann has given his Buy rating due to a combination of factors including Sera Prognostics’ progress in Medicaid pilot programs and their strategic steps towards increasing the adoption of their PreTRM test. The company is actively working on establishing a foundation for broader market penetration by focusing on coverage and reimbursement strategies, clinician awareness campaigns, and building a commercial team.
Brackmann also highlights the significance of the upcoming PRIME study publication, which is expected to provide additional data supporting future reimbursement and uptake. Although an increase in revenue and test volumes may take some time, the groundwork being laid by Sera Prognostics is seen as a positive indicator for future growth and market opportunity, justifying the Buy rating.
According to TipRanks, Brackmann is a 5-star analyst with an average return of 32.3% and a 68.09% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as Exact Sciences, Hologic, and QuidelOrtho.